Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | LPL | P06858 | 13/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18239340 | 0.88 | IRAK4 (0.44) | IRAK4LPLLIPGCA1CA2 | |
| SCHEMBL2215446 | 0.79 | IRAK4 (0.46) | IRAK4LPLLIPGCA1CA2 | |
| SCHEMBL29894116 | 0.79 | IRAK4 (0.46) | IRAK4LPLLIPGCA1CA2 | |
| SCHEMBL31500583 | 0.77 | LPL (0.40) | IRAK4LPLLIPGCA1CA2 | |
| SCHEMBL17673204 | 0.77 | LPL (0.40) | IRAK4LPLLIPGCA1CA2 | |
| SCHEMBL25346928 | 0.75 | IRAK4 (0.43) | IRAK4LPLLIPGCA1CA2 | |
| SCHEMBL18230142 | 0.75 | IRAK4 (0.43) | IRAK4LPLLIPGROCK1 | |
| SCHEMBL29734945 | 0.75 | IRAK4 (0.39) | IRAK4LPLLIPGIDO1TDO2 | |
| SCHEMBL26921066 | 0.75 | IRAK4 (0.39) | IRAK4LPLLIPGIDO1TDO2 | |
| SCHEMBL22150123 | 0.75 | AAK1 (0.36) | IRAK4LPLLIPGROCK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| WO-2016180537-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | BRCA1, NQO2, NQO1 | IRAK4 1577/4885LPL 4519/4885LIPG 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.